MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
about
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.Polymorphisms in DNA repair genes and MDR1 and the risk for non-Hodgkin lymphoma.Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?Relationship between P-glycoprotein and second-generation antipsychotics.Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies.Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver.Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis.Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer.Implications of pharmacogenetics for individualizing drug treatment and for study design.Intestinal drug absorption and bioavailability: beyond involvement of single transport function.Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.ABC of oral bioavailability: transporters as gatekeepers in the gut.MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression.Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.HPLC Determination of Fexofenadine in Human Plasma For Therapeutic Drug Monitoring and Pharmacokinetic Studies.The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique.Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemiaDiscordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.Multidrug resistance in epilepsy: a pharmacogenomic update.The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.ESRD impairs nonrenal clearance of fexofenadine but not midazolam.Gender and interindividual variability in pharmacokinetics.Pharmacokinetics in special populations.Drug transporters and renal drug disposition in the newborn.Fexofenadine hydrochloride in the treatment of allergic disease: a reviewInterplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes.
P2860
Q28286926-4A139629-D6AF-4D74-9585-B3A17CF95055Q33460512-E682D677-1F8E-482F-A41D-C88365906ECFQ33580765-1B57C7F2-FCAA-4628-AC2F-258E26235151Q33714593-6BDD64D6-3D4C-403F-B8BB-3BD494E2235CQ34190195-56B33225-D871-4AB0-B252-5A07D4005C56Q34208133-BD52F53D-9266-4B5E-9D5F-5E97DD7B8958Q34283903-619B72DA-767A-4FB0-956F-D14F386B5A66Q34327594-2639FC29-5ADD-4A3E-8976-DB0F277107F1Q34400733-792BFE81-BD5E-4097-B021-67C54BB2B07CQ34490600-758F9C7F-2D18-4014-A738-D0292ED5605CQ34538009-6D0B81BE-93D9-4483-AD0E-63D4DB337417Q34994901-36ABEBBE-C067-40FB-83D6-4D8A063C4536Q35070434-311B2C3A-E094-4879-AF4D-93499B8248A2Q35071734-11213E2D-831F-45A7-AB63-42D698C7E904Q35102211-A0D1B101-7897-4DFD-A7A6-6FD8B8E706E0Q35153169-22F9027F-005D-4A80-9BF9-3D64F42913B3Q35164664-41654448-0711-4F9B-98DA-3A40FABC807EQ35591517-5921324E-6FAF-4630-8B59-0486369EE60EQ35826490-6088A60F-74B7-481F-8CD6-21F1F2A989C6Q35827187-A88CF0B5-8821-4E8B-8A80-FC542B48258CQ35827580-6F187276-A168-464F-AC9B-3C2583F3C9CEQ35844186-EF4752F8-8672-48A4-B169-FE15D1D42660Q35846680-E1EF9A02-2BF5-4114-BDCB-C41F6B47E003Q35863379-2ED7E544-3CFE-4D57-9ED0-EC5C6FAA217BQ36120816-A8652DF4-1747-4646-BCDE-E4CF58D4FE48Q36186945-9C1B627A-BEAE-43D3-92CE-64E430512F33Q36301589-E89DB615-5674-4AB7-9DBC-94407BF0C769Q36326210-98A4AB9A-60E0-43BF-B255-4E02678C82B4Q36349672-C4527B39-8EA7-4604-96C7-4328F47DF14AQ36592129-9DBA5CAF-2EC6-42E0-8ADA-8039D4036184Q36605135-BD98D524-CB44-43EE-B0FD-0C702C3A3FDCQ36701911-00423DEB-A10B-47E3-AD81-3E61233890A9Q36895830-1810387E-E6FF-4685-BF7F-3594E409FC72Q37024001-A435D340-8C7B-4662-9976-8C916DA67DF2Q37367679-882BE442-DB11-4F4A-8C8B-48C56D10506FQ37550556-883010E1-31E7-4432-A8AB-0EFA351E78BFQ37550561-CB38B47F-3527-4339-A360-9F7B4BE334D3Q37635181-BDA337D6-777E-4AC4-A1A0-D331B693EE38Q37857671-ADA388EC-774A-41FB-AD44-962ED95F874EQ37964574-1A639C26-4DFA-45AB-8D14-65476F0666B3
P2860
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
@ast
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
@en
type
label
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
@ast
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
@en
prefLabel
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
@ast
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
@en
P2093
P2860
P1476
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
@en
P2093
Martin F Fromm
Matthias Schwab
Michel Eichelbaum
Monika Hitzl
Siegfried Drescher
Ulrich Brinkmann
P2860
P304
P356
10.1046/J.1365-2125.2002.01591.X
P407
P577
2002-05-01T00:00:00Z